BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22339843)

  • 1. [An interpretation of expert panel consensus statement on prevention and treatment of anthracycline cardiotoxicity].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):727-8. PubMed ID: 22339843
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
    Salvatorelli E; Menna P; Minotti G
    Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity and anthracyclines.
    Stebbing J; Jones A; Barrett-Lee P
    Breast Cancer Res Treat; 2008 Feb; 107(3):451-3. PubMed ID: 18167621
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis].
    Safonova SA; Gershanovich ML; Punanov IuA
    Vopr Onkol; 2006; 52(5):590-2. PubMed ID: 17168373
    [No Abstract]   [Full Text] [Related]  

  • 11. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Late-onset anthracycline-induced cardiotoxicity].
    Pérez C; Agustí MA; Tornos P
    Med Clin (Barc); 2009 Sep; 133(8):311-3. PubMed ID: 19501849
    [No Abstract]   [Full Text] [Related]  

  • 13. Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma.
    Perel RD; Slaughter RE; Strugnell WE
    J Cardiovasc Magn Reson; 2006; 8(6):789-91. PubMed ID: 17060100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [One case report of a late cardiotoxicity after administration of low doses of anthracyclines].
    Lawson L; Masmoudi K; Fry P; Andrejak M
    Therapie; 2010; 65(3):269-70. PubMed ID: 20699083
    [No Abstract]   [Full Text] [Related]  

  • 17. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline cardiotoxicity.
    Jones RL; Swanton C; Ewer MS
    Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.